Verastem Company Leadership
| VSTM Stock | USD 5.90 0.64 9.79% |
Verastem's insiders are aggressively selling. The analysis of the overall insider sentiment regarding Verastem suggests that most insiders are panicking. Verastem employs about 73 people. The company is managed by 19 executives with a total tenure of roughly 6 years, averaging almost 0.0 years of service per executive, having 3.84 employees per reported executive.
| Daniel Paterson CEO CEO President |
Verastem's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2024-12-24 | Daniel Calkins | Disposed 28 @ 3.91 | View | ||
| 2024-12-20 | Daniel Calkins | Disposed 65 @ 4.34 | View | ||
| 2024-12-19 | Robert E Gagnon | Disposed 130 @ 4.37 | View | ||
| 2024-12-16 | Robert E Gagnon | Disposed 285 @ 4.54 | View | ||
| 2024-11-05 | Dan Paterson | Disposed 812 @ 3.84 | View | ||
| 2024-10-07 | Daniel Calkins | Disposed 6 @ 2.86 | View | ||
| 2024-09-24 | Daniel Calkins | Disposed 28 @ 2.68 | View | ||
| 2024-09-20 | Daniel Calkins | Disposed 65 @ 2.8 | View | ||
| 2024-09-19 | Dan Paterson | Disposed 184 @ 2.79 | View | ||
| 2024-07-09 | Daniel Calkins | Disposed 7 @ 2.62 | View | ||
| 2024-06-24 | Daniel Calkins | Disposed 28 @ 3.15 | View | ||
| 2024-04-05 | Daniel Calkins | Disposed 6 @ 10.87 | View | ||
| 2024-03-25 | Daniel Calkins | Disposed 25 @ 12.02 | View | ||
| 2024-03-20 | Daniel Calkins | Disposed 55 @ 11.07 | View | ||
| 2024-03-18 | Robert E Gagnon | Disposed 283 @ 10.71 | View | ||
| 2024-01-12 | Robert E Gagnon | Disposed 9204 @ 10.95 | View |
Monitoring Verastem's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Verastem |
Verastem's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Verastem's future performance. Based on our forecasts, it is anticipated that Verastem will maintain a workforce of about 70 employees by February 2025.Verastem Management Team Effectiveness
The company has return on total asset (ROA) of (0.4731) % which means that it has lost $0.4731 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3687) %, meaning that it created substantial loss on money invested by shareholders. Verastem's management efficiency ratios could be used to measure how well Verastem manages its routine affairs as well as how well it operates its assets and liabilities. As of the 8th of January 2025, Return On Tangible Assets is likely to drop to -0.7. In addition to that, Return On Capital Employed is likely to drop to -0.9. At this time, Verastem's Other Current Assets are very stable compared to the past year. As of the 8th of January 2025, Net Tangible Assets is likely to grow to about 63.3 M, while Non Current Assets Total are likely to drop about 5.2 M.As of the 8th of January 2025, Common Stock Shares Outstanding is likely to grow to about 26.6 M, while Net Loss is likely to drop (69.8 M).
Verastem Workforce Comparison
Verastem is rated second in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 500. Verastem retains roughly 73.0 in number of employees claiming about 15% of equities under Health Care industry.
Verastem Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Verastem insiders, such as employees or executives, is commonly permitted as long as it does not rely on Verastem's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Verastem insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-06-01 | 2.2222 | 20 | 9 | 376,347 | 1,870 |
| 2024-03-01 | 0.2083 | 10 | 48 | 235,036 | 232,264 |
| 2023-12-01 | 0.1111 | 1 | 9 | 25,000 | 1,689 |
| 2023-09-01 | 0.2222 | 2 | 9 | 150,000 | 1,845 |
| 2023-06-01 | 1.0 | 8 | 8 | 625,000 | 1,703 |
| 2023-03-01 | 0.375 | 3 | 8 | 4,062,235 | 21,031 |
| 2022-12-01 | 0.1818 | 2 | 11 | 317,123 | 416,431 |
| 2022-06-01 | 2.5714 | 18 | 7 | 1,052,500 | 48,680 |
| 2021-12-01 | 1.75 | 7 | 4 | 2,163,493 | 36,012 |
| 2020-06-01 | 2.3333 | 7 | 3 | 187,944 | 2,487,600 |
| 2020-03-01 | 1.3333 | 4 | 3 | 5,752,651 | 0.00 |
| 2018-09-01 | 20.0 | 20 | 1 | 627,500 | 0.00 |
| 2017-12-01 | 0.2857 | 2 | 7 | 360,538 | 450,000 |
| 2016-06-01 | 1.3333 | 8 | 6 | 565,000 | 173,707 |
| 2015-06-01 | 13.0 | 13 | 1 | 137,937 | 2,648 |
| 2015-03-01 | 1.6 | 8 | 5 | 1,866,725 | 24,062 |
| 2014-12-01 | 14.0 | 14 | 1 | 72,850 | 2,770 |
| 2014-09-01 | 0.25 | 1 | 4 | 3,000 | 22,047 |
| 2014-06-01 | 15.0 | 15 | 1 | 358,000 | 5,530 |
| 2014-03-01 | 1.1429 | 8 | 7 | 685,847 | 1,044,000 |
| 2013-09-01 | 3.0 | 15 | 5 | 64,000 | 31,838 |
| 2013-06-01 | 52.0 | 52 | 1 | 482,383 | 5,842 |
| 2013-03-01 | 6.25 | 25 | 4 | 400,900 | 77,248 |
| 2012-12-01 | 11.0 | 11 | 1 | 289,212 | 0.00 |
| 2012-09-01 | 1.5 | 3 | 2 | 856,612 | 137,142 |
| 2012-03-01 | 0.9762 | 41 | 42 | 19,461,942 | 64,076,185 |
Verastem Notable Stakeholders
A Verastem stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Verastem often face trade-offs trying to please all of them. Verastem's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Verastem's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Richard MBA | Founder Consultant | Profile | |
| Daniel Paterson | CEO President | Profile | |
| Jonathan Pachter | Chief Officer | Profile | |
| Michael Crowther | Chief Officer | Profile | |
| Sean Flynn | Gen VP | Profile | |
| MD MSc | Head Strategy | Profile | |
| Robert Weinberg | CoFounder Board | Profile | |
| Daniel Calkins | Interim Officer | Profile | |
| Lisa Buffington | Senior Advocacy | Profile | |
| Michelle MD | CoFounder | Profile | |
| Piyush Gupta | CoFounder | Profile | |
| Nate Sanburn | Senior Engagement | Profile | |
| John MD | Chief Officer | Profile | |
| BPHARM RPh | CEO Director | Profile | |
| Mba MBA | Founder Consultant | Profile | |
| Colleen Mockbee | Global Development | Profile | |
| Robert MBA | Senior Operations | Profile | |
| Cathy Carew | Chief Officer | Profile | |
| Erin Cox | Sr Communications | Profile |
About Verastem Management Performance
The success or failure of an entity such as Verastem often depends on how effective the management is. Verastem management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Verastem management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Verastem management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.67) | (0.70) | |
| Return On Capital Employed | (0.86) | (0.90) | |
| Return On Assets | (0.67) | (0.70) | |
| Return On Equity | (1.75) | (1.84) |
Verastem Workforce Analysis
Traditionally, organizations such as Verastem use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Verastem within its industry.Verastem Manpower Efficiency
Return on Verastem Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.2M | |
| Net Loss Per Executive | 4.6M | |
| Working Capital Per Employee | 1.6M | |
| Working Capital Per Executive | 6.2M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verastem. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Verastem Stock, please use our How to Invest in Verastem guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verastem. If investors know Verastem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verastem listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.14) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Verastem is measured differently than its book value, which is the value of Verastem that is recorded on the company's balance sheet. Investors also form their own opinion of Verastem's value that differs from its market value or its book value, called intrinsic value, which is Verastem's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verastem's market value can be influenced by many factors that don't directly affect Verastem's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verastem's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verastem is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verastem's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.